BG Medicine, Inc.
BGMD · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.03 | 0.04 | -0.11 |
| FCF Yield | -104.55% | -54.17% | -54.49% | -45.86% |
| EV / EBITDA | -0.39 | -1.93 | -1.89 | -1.95 |
| Quality | ||||
| ROIC | -485.83% | -203.93% | -226.15% | -223.46% |
| Gross Margin | 67.75% | 65.70% | 65.90% | 66.00% |
| Cash Conversion Ratio | 0.69 | 1.01 | 0.96 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.28% | -0.33% | 35.59% | 50.91% |
| Free Cash Flow Growth | 55.10% | 47.04% | 28.00% | -42.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 0.16 | 0.03 | 0.13 |
| Interest Coverage | -29.12 | -10.11 | -12.31 | -20.99 |
| Efficiency | ||||
| Inventory Turnover | 3.48 | 2.39 | 3.03 | 2.14 |
| Cash Conversion Cycle | -256.32 | -89.84 | -104.38 | -201.65 |